Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
68.3M
-
Shares change
-
+1.31M
-
Total reported value, excl. options
-
$2.55B
-
Value change
-
+$46.2M
-
Put/Call ratio
-
0.23
-
Number of buys
-
90
-
Number of sells
-
-73
-
Price
-
$37.28
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2021
220 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2021.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.3M shares
of 108M outstanding shares and own 63.34% of the company stock.
Largest 10 shareholders include FMR LLC (11.1M shares), WASATCH ADVISORS INC (8.12M shares), VANGUARD GROUP INC (6.89M shares), BlackRock Inc. (5.74M shares), Bellevue Group AG (3.77M shares), MARSHALL WACE, LLP (2.3M shares), LORD, ABBETT & CO. LLC (2.09M shares), TimesSquare Capital Management, LLC (1.72M shares), STATE STREET CORP (1.56M shares), and FRANKLIN RESOURCES INC (1.36M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.